| 词条 | Catridecacog |
| 释义 |
| drug_name = | IUPAC_name = | image = | alt = | caption = | pronounce = | tradename = Tretten, NovoThirteen | Drugs.com = {{drugs.com|parent|tretten}} | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = C | pregnancy_category= | licence_EU = yes | legal_AU = | legal_AU_comment = | legal_CA = | legal_NZ = | legal_UK = | legal_US = Rx-only | legal_UN = | legal_status = | routes_of_administration = Injection | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = | ATCvet = | ATC_prefix = B02 | ATC_suffix = BD11 | PubChem = | DrugBank = | ChemSpiderID = none | KEGG = D10532 | chemical_formula = | molecular_weight = }}Catridecacog (brand name Tretten in the US and NovoThirteen in Europe[1]) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014.[2] It was brought to market by Novo Nordisk.[1] References1. ^1 NHS New Drugs Online Report for catridecacog Page accessed July 2, 2015 2. ^Catridecacog: First drug to treat rare genetic blood clotting disorder. The Pharmacist February 01, 2014
2 : Antihemorrhagics|Biopharmaceuticals |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。